Zobrazeno 1 - 8
of 8
pro vyhledávání: '"R. Andrew Harkins"'
Autor:
Michelle Lee, Aseala Abousaud, R. Andrew Harkins, Ellen Marin, Deepali Balasubramani, Michael C. Churnetski, Deniz Peker, Ankur Singh, Jean L. Koff
Publikováno v:
Current Oncology Reports.
Publikováno v:
Leukemia & Lymphoma. 61:3283-3286
The growing costs of cancer therapy for an aging population [1] and the increasing cost burden of novel drugs in particular for the treatment of hematologic and other malignancies [2] continue to c...
Autor:
Christopher R. Flowers, R. Andrew Harkins, Sharvil P. Patel, C. Ileen Jhaney, Jean L. Koff, Sandeep S. Dave, Jeffrey M. Switchenko, Michelle J. Lee
Publikováno v:
Cancer. 126:3493-3503
BACKGROUND Significant racial differences have been observed in the incidence and clinical outcomes of diffuse large B-cell lymphoma (DLBCL) in the United States, but to the authors' knowledge it remains unclear whether genomic differences contribute
Autor:
R. Andrew Harkins, Sharvil P. Patel, Michelle J. Lee, Jeffrey M. Switchenko, Stephen M. Ansell, Nancy L. Bartlett, Kristie A. Blum, Amanda F. Cashen, Carla Casulo, Jonathan W. Friedberg, Patrick B. Johnston, Brad S. Kahl, John P. Leonard, Brian K. Link, Izidore S. Lossos, Peter Martin, Matt J. Maurer, Neha Mehta-Shah, Patrick M. Reagan, Jason R. Westin, Jean L. Koff, Christopher R. Flowers
Publikováno v:
Blood advances. 6(9)
Recent first-line randomized controlled trials (RCTs) for patients with diffuse large B-cell lymphoma (DLBCL) have shown negative results, which may be due in part to onerous eligibility criteria limiting enrollment of poor-risk patients who require
Publikováno v:
Clin Lymphoma Myeloma Leuk
Introduction Diffuse large B-cell lymphoma (DLBCL) is genetically and clinically heterogeneous. Despite advances in genomic subtyping, standard frontline chemoimmunotherapy has remained unchanged for years. As high-throughput analysis becomes more ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ce50335120253b1965d2a620dcd38ec
https://europepmc.org/articles/PMC7136133/
https://europepmc.org/articles/PMC7136133/
Publikováno v:
Expert Rev Pharmacoecon Outcomes Res
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and is a clinically heterogeneous disease. Treatment pathways for DLBCL are diverse and integrate established and novel therapies.Areas covered: We review the
Autor:
Michelle J. Lee, Selin Merdan, Jordan S. Goldstein, Jean L. Koff, Christopher R. Flowers, Andres Chang, R. Andrew Harkins, Sharvil P. Patel
Publikováno v:
Expert Rev Hematol
INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and is an aggressive malignancy with heterogeneous outcomes. Diverse methods for DLBCL outcomes assessment ranging from clinical to genomic have been develope
Autor:
R. Andrew Harkins, Sharvil P. Patel, Michelle J. Lee, Christopher R. Flowers, Jeffrey M. Switchenko
Publikováno v:
Blood. 134:3416-3416
PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous disease. Patients exhibit a 30%-40% relapse/refractory rate on standard first-line therapy and are known to have poor outcomes with relapsed/refractory disease, indicating a